CClinicalTrials.gg
CompletedNCT04555590Updated Feb 13, 2025

Implementation of an Evidence Based Parentally Administered Intervention for Preterm Infants

An interventional study of H-HOPE Intervention in Premature Infants and Parent-Child Relations, sponsored by Medical College of Wisconsin. Completed at 4 sites in United States. Per ClinicalTrials.gov, last updated 2025-02-13.

Sponsored by Medical College of Wisconsin · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
1,882
Allocation
Randomized
Sex
All
01

Study summary

Early developmentally-based behavioral intervention has well-established positive effects and is recommended as the standard of care to support early brain maturation, health, and development. However, few neonatal intensive care units (NICUs) provide this early intervention. H-HOPE (Hospital to Home: Optimizing the Preterm Infant's Environment) has established efficacy, and has a standardized protocol, making it ready for widespread implementation. The infant-directed component of H-HOPE provides Auditory (voice), Tactile (moderate touch massage), Visual (eye to eye), and Vestibular (rocking) stimulation starting when infants are ready for social interaction. The parent-directed component of H-HOPE includes participatory guidance and support to help parents engage with infants in the NICU and the transition to home. In this NIH-funded research, H-HOPE improved growth, developmental maturity and mother-infant interaction, and reduced initial hospitalization costs and acute care visits through 6-weeks corrected age. This research tests whether H-HOPE can be implemented and sustained in five diverse NICUs, using a Type 3 Hybrid design to evaluate both implementation processes and effectiveness. The specific aims are to: 1) Identify the degree of implementation success; 2) Evaluate the effectiveness of H-HOPE for infants, hospital costs from H-HOPE enrollment until discharge, and parents, compared to a pre-implementation comparison cohort; and 3) Determine influences (facilitators and barriers) associated with implementation success and H-HOPE effectiveness, guided by the Consolidated Framework for Implementation Research (CFIR). An incomplete stepped-wedge design guides staggered roll-out for five clinical sites. Each NICU completes the CFIR implementation steps (Planning and Engaging, Executing, and Reflecting and Evaluating), followed by 6 months of Sustaining. For Aim 1, degree of implementation success is determined every two months as Sustainability (still offering H-HOPE), Reach (% of eligible parent/infant dyads receiving H-HOPE) and Degree of Implementation (mean H-HOPE services received per parent-infant unit) (primary implementation outcomes). For Aim 2, effectiveness is analyzed using generalized linear mixed models for infant, cost, and parent outcomes (primary outcomes: infant growth at discharge and acute care visits from discharge to 6-weeks corrected age). Propensity score analysis is used to make the pre- and post-implementation comparable. For Aim 3, a mixed methods analyses is used to identify influences from H-HOPE records and interviews that are associated with implementation success and effectiveness at each site and across sites. This is the first time implementation in a NICU is guided by the evidence-based CFIR framework, and results will make a major contribution to implementation science. This study will produce an evidence-based implementation strategy and Toolkit to disseminate nationwide. Widespread H-HOPE implementation will make a significant change in clinical practice and improve preterm infant health and health care costs.

02

Conditions studied

  • Premature Infants
  • Parent-Child Relations

Browse trials for

Keywords

  • Premature Infants
  • NICU
  • Parental Stress
  • Healthcare Costs
03

In context

Premature Birth

2,554 studies on the registry are indexed under Premature Birth; 498 are open to participants now.

This study's enrollment of 1,882 is above the median of 84 across 1,689 interventional studies indexed under Premature Birth.

Browse Premature Birth studies →

Lead sponsor

Medical College of Wisconsin is the lead sponsor of 540 studies on the registry; 120 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 56 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

There are two cohorts of infants and parents: the Pre-H-HOPE Comparison Cohort and H-HOPE Cohort. H-HOPE is a family intervention, so parent(s) and infants are recruited together and must meet both parent and infant eligibility criteria. Infant and parent eligibility criteria are the same for both cohorts (Pre-H-HOPE and H-HOPE). Additionally, there are criteria for hospital personnel.

Inclusion criteria for the infant:

  • born between 23-35 weeks gestational age (GA)
  • have reached 31-32 weeks post menstrual age (PMA)
  • clinically stable
  • male or female
  • could be receiving oxygen or intravenous therapy
  • could have been previously intubated for mechanical ventilation
  • assessed as ready to begin social interaction Infants of multiple births will be eligible to participate but data from only one randomly selected infant will be used in analysis of Aim 2.

Inclusion criteria for the parent (up to 2 per infant can be in the study:

  • mother, father, other family member, or surrogate parent regardless of age, race/ethnicity, gender, or sexual orientation, or biological relationship to the infant
  • intends to act in the role of parent
  • 18 years of age or older
  • English or Spanish speaking

Inclusion criteria for hospital personnel:

Hospital Administrator - staff member with an administrative role outside of the NICU leadership who is knowledgeable about the activities of the NICU NICU Manager - Nurse or physician with an administrative role in the NICU (e.g. medical director or nurse manager) H-HOPE Team member - staff member who is part of the H-HOPE Team NICU Staff Nurse - registered nurse who provides direct patient care and works a minimum of 50% in the NICU Exclusion Criteria We will not be limiting any participants based on sex/gender, or ethnic/racial identity. Differences due to race and gender will be accounted for during data analysis. We will be limiting enrollment to English or Spanish speaking parents due to the limited availability of valid measures for data collection in languages other than English and Spanish. However, we anticipate that we will still be able to recruit an ethnically diverse group of parents because of the ethnic composition of the parents at the sites and our prior experience.

Exclusion criteria for the infant:

  • major brain injuries (e.g. cystic PVL)
  • current sepsis
  • intubated for mechanical ventilation at time of enrollment
  • surgical necrotizing enterocolitis
  • Ward of the State

Exclusion criteria for the parent:

  • positive drug screen for illegal substances
  • planning to surrender custody of the infant or legal custody remove
  • primary parent does not have legal guardianship of the infant
  • Mental health diagnosis such as Psychosis, Bipolar Disease Exclusion Criteria Hospital Personnel
  • None

Exclusion Criteria for NICU Staff Nurses:

  • less than 50% effort.
  • does not provide direct patient care
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,882 participants (actual)

Study arms

  • No intervention
    Pre H-HOPE Cohort

    The Pre-H-HOPE Comparison Cohort will not receive the H-HOPE intervention, and represents the prior standard (non-HOPE).

  • Experimental
    H-HOPE Cohort

    The H-HOPE Cohort will receive the H-HOPE intervention.

    Behavioral: H-HOPE Intervention

Interventions

  • BehavioralH-HOPE Intervention

    The H-HOPE intervention (Hospital to Home: Optimizing the Preterm Infant's Environment) to promote early infant development and parental engagement. H-HOPE includes ATVV, which provides Auditory (voice), Tactile (moderate touch massage), Visual (eye to eye), and Vestibular (rocking) stimulation with a parent-directed component which provides participatory guidance and social support to engage with their infants.

06

What researchers measure

Primary outcomes

  1. Aim 1 Outcome Measure: Implementation Success (Percent Change in Sustainability throughout implementation)

    Change in % of instances of H-HOPE being offered

    Time frame: Every 2 months from Executing through 6 months after supported implementation ends

  2. Aim 1 Outcome Measure: Implementation Success (Change in Reach throughout implementation)

    % of eligible parent-infant units receiving H-HOPE

    Time frame: Every 2 months from Executing through 6 months after supported implementation ends

  3. Aim 1 Outcome Measure: Implementation Success (Degree of Implementation)

    In-Hospital: Infant: Mean number of ATVV interventions received per eligible day (Range 0-2) Transition to home: Parents: # received participatory guidance sessions (2 pre-discharge and 2 screen time visits at 2-3 days and 7-15 days post-discharge; Range: 0-3) Infant: Mean number of ATVV interventions received by per eligible day since discharge (Range 0-2; provided and reported by parent)

    Time frame: Every 2 months from Executing through 6 months after supported implementation ends

  4. Aim 2 Outcome Measure: Effectiveness-(Change in Infant Head Circumference)

    Infant Primary: Infant Head Circumference, measured in centimeters.

    Time frame: From birth to discharge (an average of 31- 48 weeks PMA (Post Menstrual Age) of infant)

  5. Aim 2 Outcome Measure: Effectiveness (Change in Infant Weight)

    Infant Primary: Weight, measured in kilograms

    Time frame: From birth to discharge (an average of 31- 48 weeks PMA (Post Menstrual Age) of infant)

  6. Aim 2 Outcome Measure: Effectiveness (Change in Infant Length)

    Infant Primary: Length, measured in centimeters

    Time frame: From birth to discharge (an average of 31- 48 weeks PMA (Post Menstrual Age) of infant)

  7. Aim 2 Outcome Measure: Effectiveness (Change in number of Acute Care Visits)

    Number of acute care visits (clinic or emergency department visit or re-hospitalization)

    Time frame: At 6 weeks post discharge

Secondary outcomes

  1. Aim 2 Outcome Measure: Cost

    Mean hospitalization cost/day (direct costs) from entry into H-HOPE through discharge, adjusted by adding the cost per H-HOPE infant to implement H-HOPE (training, coordinating, time to deliver H-HOPE and to arrange screen time visits)

    Time frame: From infant enrollment through infant discharge (an average of 31- 48 weeks PMA (Post Menstrual Age) of infant)

  2. Aim 3 Outcome Measure: CFIR influences (Number of facilitators and barriers to implementation)

    Aim 3 uses mixed methods analyses to integrate data collected for this aim regarding influences (facilitators or barriers) in each of the 5 CFIR domains with data from Aim 1 (implementation success) and Aim 2 (effectiveness for the primary infant outcomes).

    Time frame: From the completion of the first site's Sustaining Phase through Final Analysis of all site data, estimated to be 39 months.

Other outcomes

  1. Aim 2 Exploratory Outcome Measure: # Parent NICU visits/days of hospitalization

    # Parent NICU visits/days of hospitalization (each parent)

    Time frame: At discharge (an average of 31- 48 weeks PMA (Post Menstrual Age) of infant)

  2. Aim 2 Exploratory Outcome Measure: Parental Stress (Anxiety)

    PROMIS SF v1.0 - Anxiety7a

    Time frame: At discharge (an average of 31- 48 weeks PMA (Post Menstrual Age) of infant) and 6 weeks corrected Age

  3. Aim 2 Exploratory Outcome Measure: Parental Stress (Depression)

    PROMIS SF v1.0 - Depression 8b

    Time frame: At discharge (an average of 31- 48 weeks PMA (Post Menstrual Age) of infant) and 6 weeks corrected Age

  4. Aim 2 Exploratory Outcome Measure: Parental Stress (Child Health Worry Scale)

    Child Health Worry Scale. The scale values are 1=not worried; 2=somewhat worried; 3=moderately worried; 4=very worried; 5=extremely worried

    Time frame: At discharge (an average of 31- 48 weeks PMA (Post Menstrual Age) of infant) and 6 weeks corrected Age

  5. Aim 2 Exploratory Outcome Measure: Confidence in Care

    (KPCS) Karitane Parenting Confidence Scale. The following choices are available to select for each of the scale's questions: No, hardly ever (0 points) , No, not very often (1 point), Yes, some of the time (2 points), Yes, most of the time (3 points). The points are added up and a total score is calculated. Parents with a total score of 39 or less may be experiencing low levels of parenting confidence.

    Time frame: At discharge (an average of 31- 48 weeks PMA (Post Menstrual Age) of infant) and 6 weeks corrected Age

07

Study locations

4 sites
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Advocate Aurora Health
    Park Ridge, Illinois 60068, United States
  • Duke Univesity
    Durham, North Carolina 27708, United States
  • Children's Hospital of Wisconsin
    Milwaukee, Wisconsin 53201, United States
08

References and documents

Publications

  • White-Traut R, Brandon D, Kavanaugh K, Gralton K, Pan W, Myers ER, Andrews B, Msall M, Norr KF. Protocol for implementation of an evidence based parentally administered intervention for preterm infants. BMC Pediatr. 2021 Mar 24;21(1):142. doi: 10.1186/s12887-021-02596-1. PubMed 33761902 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04555590
Lead sponsor
Medical College of Wisconsin
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Duke University, University of Chicago, Wake Forest University Health Sciences, Children's Hospital and Health System Foundation, Wisconsin
Responsible party
Rosemary White-Traut (Director of Nursing Research and Evidence Based Practice, Medical College of Wisconsin) — Principal investigator
First posted
Sep 18, 2020
Start date
Nov 16, 2020
Primary completion
Nov 5, 2024
Completion
Nov 5, 2024
Last update
Feb 13, 2025

Study contacts

Rosemary White-Traut, PhD,RN,FAAN
principal investigator · Department of Nursing Research and Evidence-Based Practice Children's Wisconsin

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion